Vytrus Biotech Statistics

Total Valuation

Vytrus Biotech has a market cap or net worth of EUR 31.07 million. The enterprise value is 30.87 million.

Market Cap	31.07M
Enterprise Value	30.87M

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Vytrus Biotech has 7.54 million shares outstanding. The number of shares has increased by 11.10% in one year.

Current Share Class	7.54M
Shares Outstanding	7.54M
Shares Change (YoY)	+11.10%
Shares Change (QoQ)	+12.82%
Owned by Insiders (%)	34.55%
Owned by Institutions (%)	15.25%
Float	3.72M

Valuation Ratios

The trailing PE ratio is 44.59 and the forward PE ratio is 29.94.

PE Ratio	44.59
Forward PE	29.94
PS Ratio	5.93
PB Ratio	4.56
P/TBV Ratio	10.68
P/FCF Ratio	23.58
P/OCF Ratio	22.25
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 22.25, with an EV/FCF ratio of 23.44.

EV / Earnings	44.31
EV / Sales	5.89
EV / EBITDA	22.25
EV / EBIT	48.79
EV / FCF	23.44

Financial Position

The company has a current ratio of 3.28, with a Debt / Equity ratio of 0.30.

Current Ratio	3.28
Quick Ratio	2.79
Debt / Equity	0.30
Debt / EBITDA	1.46
Debt / FCF	1.54
Interest Coverage	4.85

Financial Efficiency

Return on equity (ROE) is 11.77% and return on invested capital (ROIC) is 4.93%.

Return on Equity (ROE)	11.77%
Return on Assets (ROA)	3.98%
Return on Invested Capital (ROIC)	4.93%
Return on Capital Employed (ROCE)	6.61%
Revenue Per Employee	149,640
Profits Per Employee	19,908
Employee Count	35
Asset Turnover	0.53
Inventory Turnover	0.96

Taxes

Income Tax	-140,884
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +28.15% in the last 52 weeks. The beta is 0.11, so Vytrus Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.11
52-Week Price Change	+28.15%
50-Day Moving Average	3.46
200-Day Moving Average	2.70
Relative Strength Index (RSI)	74.97
Average Volume (20 Days)	7,262

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Vytrus Biotech had revenue of EUR 5.24 million and earned 696,782 in profits. Earnings per share was 0.09.

Revenue	5.24M
Gross Profit	4.75M
Operating Income	632,748
Pretax Income	555,898
Net Income	696,782
EBITDA	1.39M
EBIT	632,748
Earnings Per Share (EPS)	0.09

Full Income Statement

Balance Sheet

The company has 2.22 million in cash and 2.03 million in debt, giving a net cash position of 193,389 or 0.03 per share.

Cash & Cash Equivalents	2.22M
Total Debt	2.03M
Net Cash	193,389
Net Cash Per Share	0.03
Equity (Book Value)	6.81M
Book Value Per Share	0.90
Working Capital	2.46M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.40 million and capital expenditures -78,804, giving a free cash flow of 1.32 million.

Operating Cash Flow	1.40M
Capital Expenditures	-78,804
Free Cash Flow	1.32M
FCF Per Share	0.17

Full Cash Flow Statement

Margins

Gross margin is 90.61%, with operating and profit margins of 12.08% and 13.30%.

Gross Margin	90.61%
Operating Margin	12.08%
Pretax Margin	10.61%
Profit Margin	13.30%
EBITDA Margin	26.49%
EBIT Margin	12.08%
FCF Margin	25.15%

Dividends & Yields

Vytrus Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.10%
Shareholder Yield	n/a
Earnings Yield	2.24%
FCF Yield	4.24%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Vytrus Biotech has an Altman Z-Score of 3.66 and a Piotroski F-Score of 6.

Altman Z-Score	3.66
Piotroski F-Score	6